ABSTRACT: Recent advances in embryo freezing technology together with growing concerns over multiple births have shifted the paradigm of appropriate IVF. This has led to the adoption of new performance indicators for ART clinics by national reporting schemes, such as those curated by the Society for Assisted Reproductive Technology (SART) and the Human Fertilization and Embryology Authority (HFEA). Using these organizations as case studies, we review several outcome measures from a statistical perspective. We describe several denominators that are used to calculate live birth rates. These include cumulative birth rates calculated from all fresh and frozen transfer procedures arising from a particular egg collection or cycle initiation, and live birth rates calculated per embryo transferred. Using data from both schemes, we argue that all cycles should be included in the denominator, regardless of whether or not egg collection and fertilization were successful. Excluding cancelled cycles reduces the impact of confounding due to patient characteristics but also removes policy and performance differences which we argue represent relevant sources of variation. It may be misleading to present prospective patients with essentially hypothetical measures of performance predicated on parity of ovarian stimulation and transfer policies. Although live birth per embryo has the advantage of encouraging single embryo transfer, we argue that it is prone to misinterpretation. This is because the likelihood of live birth is not proportional to the number of embryos transferred. We conclude that it is not possible to present a single measure that encompasses both effectiveness and safety. Instead, we propose that a set of clear, relevant outcome indicators is necessary to enable subfertile patients to make informed choices regarding whether and where to be treated.
Introduction
IVF is a financially and emotionally burdensome treatment which, for the majority of patients, will end in failure. Most subfertile patients seek information about their condition online (Haagen, et al., 2003; Rawal and Haddad, 2006; Talarczyk, et al., 2012) . Meanwhile, direct to consumer advertising of ART is ubiquitous (Huang, et al., 2005; Abusief, et al., 2007; Wilkinson, et al., 2017) . Clinics compete for patients, creating a strong incentive to selectively report success rates in a manner that presents their performance as superior. The situation is particularly troubling, as the multistage nature of IVF introduces an extensive menu of numerators (such as live birth, or various stages of pregnancy) and denominators (such as the started cycle, transfer procedure or individual embryo transferred) for this purpose (Heijnen, et al., 2004; Wilkinson, et al., 2016 Wilkinson, et al., , 2017 . Since individual clinics have no incentive to collaborate to provide consistent reporting of success rates, it falls to national reporting schemes to meet this challenge.
Historically, national reporting schemes such as those curated by the Society for Assisted Reproductive Technology (SART) in the USA or the Human Fertilization and Embryology Authority (HFEA) in the UK have emphasized live birth outcomes calculated in all fresh treatment cycles started. However, the widespread adoption of frozen embryo transfer together with growing concerns over the rate of multiple births has led to registries supplementing or changing the measures that they use to evaluate IVF programmes. Although the challenge of providing relevant information while protecting patients remains the same wherever IVF is offered, different strategies have emerged in response. In the following article, we consider these strategies and their implications from a statistical perspective.
Case study 1: SART SART now present the outcome 'preliminary cumulative outcome per intended egg retrieval' at the top of the performance report for each of their member clinics on their 'Find a Clinic' facility (Society for Assisted Reproductive Technology, 2016). This includes live birth events arising from all fresh and frozen transfers of embryos resulting from a cycle. The emphasis on this cumulative numerator reduces the incentive to transfer multiple embryos in the initial fresh transfer, because it ensures that this practice is not rewarded over the safer, and potentially more successful (Roberts, et al., 2011) , option of transferring one embryo at a time in a series of transfer procedures. Importantly, the denominator includes all 'intended' egg retrievals, so that any cycles cancelled prior to egg collection are included as failed treatments. Beneath this, the report presents live birth event in the first transfer procedure for each intended egg collection (cycle started), live birth per frozen cycle started and live birth per patient, which includes the outcome of any treatments undertaken by a new patient starting treatment at the clinic in the reporting year. SART's approach then has been to introduce and emphasize outcome measures that take into account all of the stages of treatment undertaken by patients, from the start of ovarian stimulation to the outcome of any subsequent transfer procedures. Consequently, the chosen measures are both clear and relevant to potential patients.
Case study 2: HFEA
Following an extensive consultation process (Human Fertilization and Embryology Authority, 2014) , HFEA have announced changes to the way they report success rates through their online 'Choose a Fertility Clinic' facility, a beta version of which is currently publically available (Human Fertilization and Embryology Authority, 2016) . The headline figure now presented for each clinic is 'live birth event per embryo transferred'. This counts birth events arising from each transfer procedure in the numerator, but increases the denominator by one for each individual embryo transferred to a patient (Abdalla, et al., 2010) . Consequently, there is a penalty for multiple embryo transfer. If twins result from a double embryo transfer, live birth event per embryo transferred is ½ = 0.5. Patients who do not undergo a transfer procedure are excluded from the calculation. Beneath this, HFEA present 'cumulative live birth event per egg collection'. As for the cumulative birth measure reported by SART, this counts birth events resulting from the transfer of any embryos created from the oocytes obtained in a single egg collection. The two measures differ, however, in the fact that HFEA's version excludes patients who have their cycles cancelled prior to egg collection. Both of the measures emphasized in HFEA's new reporting standard, therefore, exclude a proportion of patients undergoing unsuccessful treatment. Prospective patients must navigate to separate 'Detailed Statistics' pages to find live birth events per cycle started, and cumulative birth rates per cycle started are not presented.
Consequences of excluding cancelled cycles
The numbers of patients who start ovarian stimulation but do not achieve egg collection or embryo transfer are nontrivial relative to the likelihood that treatment will be successful. Taking the 2014 figures from SART's most recent National Summary Report as an example, 9247 of 102 982 (9%) cycles started did not reach the egg collection stage, and of the 93 730 collections that do take place, 7188 (8%) had no embryos available for transfer (Society for Assisted Reproductive Technology, 2016). Outcome measures that exclude failed cycles effectively assume successful ovarian stimulation and fertilization and, therefore, exaggerate the chance of success for prospective patients.
Proponents of live birth event per embryo transferred have argued that the exclusion of cancelled cycles is actually an advantage of using the measure (Abdalla, et al., 2010) . In particular, it is argued that cycle cancellation is largely driven by the prognostic characteristics of patients. Removing the initial stages of treatment from consideration removes not only much of the confounding due to differences in patient characteristics between centres, but also differences due to the variety of clinic embryo transfer policies. The strength of live birth event per embryo transferred as a measure, it is claimed, is that it compares clinics purely in terms of the quality of the embryos they produce in their labs (Abdalla, et al., 2010) .
This line of argument can be challenged. First, there is the matter of what should and should not be controlled for when comparing treatment programmes. It is indeed desirable to take differences in patient characteristics into account, lest confounding by indication obfuscate genuine differences in performance (Walker, 1996) . It is less desirable to control for relevant differences in the treatment programmes themselves, however, since it is these differences that account for much of the variation in success rates between clinics. Second, differences in patient characteristics may influence the uterine environment in addition to the stimulation and fertilization stages (Roberts, et al., 2010) , so are not fully resolved by the embryo selection process.
The variation in cancellation rates is demonstrated in Fig. 1 , which displays the proportions of cycles cancelled prior to oocyte retrieval in 62 clinics in the UK. The search strategy is contained in Supplementary Data I and the data are available at goo.gl/lKxQwz . This is not an exhaustive list of UK clinics, but is a sample of sufficient size to illustrate the point at hand. The left panel shows the data for patients of all ages, ordered by cancellation rate. There is clear variation in cancellation rates. The right hand panel shows the cancellation rates for patients under 35 years of age, using the same ordering as the left hand panel. By limiting our attention to patients under 35, we reduce (but do not remove) variation due to patient characteristics. Moreover, younger patients will have higher ovarian reserve on average, and it is in this group that there is greatest scope for variation in ovarian response according to the clinic stimulation strategy (Fleming, et al., 2013) . Clearly, the right hand panel shows that there remains considerable variation in cancellation rates, even after allowing for the increase in uncertainty arising from reduced sample sizes. It is artificial to pretend that these differences do not exist by choosing outcome measures that eliminate them from consideration.
How to interpret live birth per embryo transferred?
Live birth per embryo transferred aims to measure clinic performance in embryo transfer were all other differences in treatment to be removed from consideration. This may have value for regulators and commissioners of services. However, for patients this does not represent a comparison between actual treatment outcomes. Instead, it provides pseudo-information about a state of affairs that does not actually exist. Aside from this, there are other obstacles to interpretation, arising from the fact that the outcomes of multiple embryos transferred to the same patient are not statistically independent. For example, suppose we have a 'live birth event per embryo transferred' rate of 26% for some clinic. A patient might look at this and think that if they have two embryos transferred then the chance of success will be 52%, indicating that it would be more likely than not that they would have a baby. It is wrong, but not unreasonable, for a patient to arrive at this conclusion, because any statistic presented 'per unit' implies that if you have more units you will have proportionally more events. This is clearly not the case for live birth events per embryo transferred, because whether or not an embryo implants is partially determined by factors that have nothing to do with the embryos themselves. This immediately presents a serious concern, as it presents double embryo transfer as an attractive option. A technical consequence of this statistical dependency is that it is not possible to calculate valid confidence intervals on the basis of the total number of births and the total number of embryos transferred (Vail and Gardener, 2003) .
Do the measures encourage safe treatments?
One motivation behind such measures as 'live birth per embryo transferred' and 'cumulative live birth per egg collection' is to promote patient safety by disincentivising multiple embryo transfer. However, while multiple births are a serious concern, they do not represent the only potential adverse consequence of treatment. Excessive response to ovarian stimulation is associated with increased risk of ovarian hyperstimulation syndrome (OHSS) (Steward, et al., 2014) and of preterm birth and low birthweight (Sunkara, et al., 2015) . Meanwhile, analyses of large national databases have revealed that many stimulation cycles result in the retrieval of >15 oocytes; the figure has been We note that a consensus definition of severe OHSS appears to be lacking. This should be a focus of fertility outcomes research. OHSS, ovarian hyperstimulation syndrome.
estimated as 17% in the UK (Sunkara, et al., 2011) and 28% in the USA (Steward, et al., 2014) . Outcome measures that exclude the stimulation phase do not penalize, and may actually encourage, harsh stimulation strategies as clinics pursue larger oocyte yields to permit multiple frozen transfer procedures. The lesson here is that we should not attempt to devise a single outcome measure that quantifies a clinic's safety and effectiveness because this approach removes the ability to consider each of these factors separately (Braakhekke, et al., 2015) . Instead, it would be more appropriate to require adverse events to be explicitly reported, so that this information can be taken into account by potential patients. In Table I , we give an example of a set of outcomes covering effectiveness and safety which could be adopted by national reporting schemes.
Conclusion
Developments to IVF have created new challenges for national reporting schemes. A major motivation is to protect patients from unsafe treatments. One strategy to address these issues is to introduce innovative outcome measures designed to discourage superficially attractive, but ultimately detrimental practices. However, some of these measures encourage safe practices at the expense of providing clear, relevant information to couples. This is neither desirable nor necessary. A prospective patient must decide whether and where to undergo treatment prior to the start of ovarian stimulation. Pertinently, psychological and physical burden of treatment (Verberg, et al., 2008; Troude, et al., 2014) and of ovarian stimulation in particular (Verberg, et al., 2008) have been identified as predictors of treatment discontinuation. Outcome measures that ignore the stimulation phase, therefore, do not assess clinic performance in the dimensions that are important to many patients.
Attempts to adjust for differences in patient characteristics through choice of outcome measure are misguided. For example, the measure 'live birth event per embryo transferred' throws the baby out with the bathwater, by not only reducing the impact of patient characteristics but also removing relevant policy and performance variation. The ability to quantify relevant variation is a prerequisite of a useful performance indicator (Bird, et al., 2005) . We would recommend either presenting success rates that are statistically adjusted for key confounders, or presenting 'headline' results stratified according to these relevant prognostic variables. This raises concerns about small sample sizes within strata, but we would agree with the suggestion that results should be presented over longer periods of time to reduce the impact of random noise (Chetkowski, 2014) .
The availability of independently validated clinic-level success rates is a potentially powerful resource for patients, and one that is denied to many prospective patients around the world who must rely upon clinics' own advertising, which may be prone to reporting biases (Wilkinson, et al., 2017) . This is not statistical pedantry; the outcomes presented are used by vulnerable people facing a potentially lifechanging decision. It is, therefore, essential that this information remains relevant and easy to understand, so as not to unintentionally mislead prospective patients and thereby deny them the opportunity to make a truly informed choice. Emphasizing a small set of several outcome measures may be one way to achieve this.
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